PRE-MARKET MOVERS

 

UPGRADES

3. AGN, HZNP, TEVA:Mizuho cut $hznp PT ahead of earnings. CS upgrades $teva to outperform. Barclays reiterates = weight for $agn.
8. CVX:$CVX upgraded to Buy at Goldman Sachs
9. DE:$DE upgraded to Outperform at Baird
13. INVA:$inva upgraded to outperform by Cowen.
20. QCOM:$QCOM upgraded to Buy at Nomura
23. TEVA:$TEVA upgraded to Outperform at Credit Suisse – PT cut $52 from $59

 

DOWNGRADES

3. BIDU:$BIDU downgraded to Neutral at Macquarie
7. HD:$HD downgraded to neutral at PiperJaffray
13. NKE:$NKE downgraded to Underperform at Bank of America
16. XOM:$XOM downgraded to Neutral at GoldmanSachs

 

EARNINGS

 

Trending Social Alerts

1. ARIA:$ARIA – brigatinib PDUFA April 29, 2017.
4. CAH:$CAH Cardinal Health Q1 17 Earnings Results: -Adj EPS: $1.24 -Revenue: $32B

 

Trending News Headlines

1. GE to Combine Oil and Gas Business With Baker Hughes

General Electric reached a deal to combine its oil-and-gas business with Baker Hughes, creating a publicly traded energy powerhouse that would give GE a cost-effective way to play any recovery in the industry.

2. Bauer ice hockey gear maker files bankruptcy in U.S. and Canada

Performance Sports Group Ltd (PSG.TO) (PSG.N), the maker of Bauer ice hockey gear, said on Monday it has filed for bankruptcy protection in the United States and Canada to facilitate a restructuring and sale of almost all of its assets.

3. TeamHealth to be Acquired by Blackstone

KNOXVILLE, Tenn., Oct. 31, 2016 /PRNewswire/ — TeamHealth Holdings, Inc. (“TeamHealth” or the “Company”) (NYSE:…

4. Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology

Ophthotech Corporation today announced that the Phase 2b study results of Fovista® , the Company’s anti-PDGF agent administered in combination with Lucentis® anti-VEGF therapy for the treatment of wet age-related macular degeneration , have been published online in Ophthalmology®, the journal of

5. ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation

ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of SERENE, a Phase II study with pimavanserin for the treatment of agitation in patients with Alzheimer’s disease

6. Why After A Massive Run, CoLucid Shares Still Look Attractive

Mirgraine, CoLucid, NASDAQ:CLCD, BioNap, JNapodano, lasmiditan

7. MGM Resorts ready to bet up to $10 billion on Japan casino, possibly via REIT

Las Vegas-based MGM Resorts International (MGM.N) could plow almost $10 billion into a Japanese casino via a publicly traded real estate investment trust, its chief executive said on Monday, as Tokyo inches closer to legalizing the industry.

8. CenturyLink to Buy Level 3 Communications for $25 Billion

CenturyLink Inc. said Monday that it reached a cash-and-stock deal to buy Level 3 Communications Inc. for roughly $25 billion, a marriage that would give the communications companies more heft to weather a competitive landscape.

9. GE Nears Deal to Combine Oil-and-Gas Business With Baker Hughes

General Electric Co. is nearing a roughly $30 billion deal to combine its oil-and-gas business with Baker Hughes Inc., creating an energy powerhouse that would give GE a cost-effective way to play any recovery in the industry.

Technology News
Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Share This

Share this post with your friends!